[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100462691":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":190,"collaborators":25,"id":192,"slug":193,"hasResults":194,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":25,"eligibilityCriteria":198,"healthyVolunteers":194,"sex":199,"minAge":200,"maxAge":25,"enrollmentInfo":201,"targetDuration":25,"studyType":204,"phases":205,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},{"fullName":5,"class":6},"Regor Pharmaceuticals Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","RGT-419B given alone as monotherapy",[13],"Drug: RGT-419B",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm B","RGT-419B in combination with Hormonal Therapy",[18],"Drug: RGT-419B in combination with hormonal therapy",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","RGT-419B","oral capsules",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"RGT-419B in combination with hormonal therapy","RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Joanna Dojillo, MSc","CONTACT","617-315-9070","joanna.dojillo@regor.com",{"name":37,"role":33,"phone":34,"phoneExt":25,"email":38},"Regor Pharmaceuticals Central Office","rgt-419b_01-101@regor.com",[40,62,79,90,106,127,148,169],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"University of California, San Diego","RECRUITING","La Jolla","California","92037","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-117.2742,32.84727,{"lat":52,"lon":51},[55,59],{"name":56,"role":33,"phone":57,"phoneExt":25,"email":58},"Sauntee Braddock","858-534-8248","sbraddock@health.ucsd.edu",{"name":60,"role":61,"phone":25,"phoneExt":25,"email":25},"Rebecca Shatsky, MD","PRINCIPAL_INVESTIGATOR",{"facility":63,"status":42,"city":64,"state":44,"zip":65,"country":46,"countryCode":47,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"University California, Los Angeles","Los Angeles","90404",{"type":49,"coordinates":67},[68,69],-118.24368,34.05223,{"lat":69,"lon":68},[72,77],{"name":73,"role":33,"phone":74,"phoneExt":75,"email":76},"Monica Rocha","310-998-4747","16910","mprocha@mednet.ucla.edu",{"name":78,"role":61,"phone":25,"phoneExt":25,"email":25},"Saeed Sadeghi, MD",{"facility":80,"status":81,"city":82,"state":83,"zip":84,"country":46,"countryCode":47,"cosmosGeoPoint":85,"geoPoint":89,"contacts":25},"Hem-Onc Associates of the Treasure Coast","ACTIVE_NOT_RECRUITING","Port Saint Lucie","Florida","34952",{"type":49,"coordinates":86},[87,88],-80.35033,27.29393,{"lat":88,"lon":87},{"facility":91,"status":42,"city":92,"state":83,"zip":93,"country":46,"countryCode":47,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Moffitt Cancer Center","Tampa","33612",{"type":49,"coordinates":95},[96,97],-82.45843,27.94752,{"lat":97,"lon":96},[100,104],{"name":101,"role":33,"phone":102,"phoneExt":25,"email":103},"Taylor L Whann","813-745-0824","Taylor.LewisWhann@moffitt.org",{"name":105,"role":61,"phone":25,"phoneExt":25,"email":25},"Heather Han, MD",{"facility":107,"status":42,"city":108,"state":109,"zip":110,"country":46,"countryCode":47,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Emory University","Atlanta","Georgia","30322",{"type":49,"coordinates":112},[113,114],-84.38798,33.749,{"lat":114,"lon":113},[117,121,125],{"name":118,"role":33,"phone":119,"phoneExt":25,"email":120},"Ashley Trumbull, MS","404-778-3969","Ashley.lynn.trumbull@emory.edu",{"name":122,"role":33,"phone":123,"phoneExt":25,"email":124},"Kathleen Coleman","404.251.1278","kathleen.marie.coleman@emory.edu",{"name":126,"role":61,"phone":25,"phoneExt":25,"email":25},"Kevin Kalinsky, MD, MS",{"facility":128,"status":42,"city":129,"state":130,"zip":131,"country":46,"countryCode":47,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Massachusetts General Hospital","Boston","Massachusetts","02142",{"type":49,"coordinates":133},[134,135],-71.05977,42.35843,{"lat":135,"lon":134},[138,142,146],{"name":139,"role":33,"phone":140,"phoneExt":25,"email":141},"Amber Newton","617-726-1634","ANEWTON3@mgh.harvard.edu",{"name":143,"role":33,"phone":144,"phoneExt":25,"email":145},"Abigail Fessele","(P): 617-724-8305","afessele@mgh.harvard.edu",{"name":147,"role":61,"phone":25,"phoneExt":25,"email":25},"Seth Wander, MD",{"facility":149,"status":42,"city":150,"state":151,"zip":152,"country":46,"countryCode":47,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Washington University School of Medicine","St Louis","Missouri","63110",{"type":49,"coordinates":154},[155,156],-90.19789,38.62727,{"lat":156,"lon":155},[159,163,167],{"name":160,"role":33,"phone":161,"phoneExt":25,"email":162},"Sammie Ruzicka, LMSW","314-747-5209","ruzicka@wustl.edu",{"name":164,"role":33,"phone":165,"phoneExt":25,"email":166},"Tracy Summa, CCRP","314.362.0263","tracy.summa@wustl.edu",{"name":168,"role":61,"phone":25,"phoneExt":25,"email":25},"Katherine Clifton, MD",{"facility":170,"status":42,"city":171,"state":172,"zip":173,"country":46,"countryCode":47,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"New York Cancer and Blood Specialists","Port Jefferson Station","New York","11776",{"type":49,"coordinates":175},[176,177],-73.04733,40.92538,{"lat":177,"lon":176},[180,184,188],{"name":181,"role":33,"phone":182,"phoneExt":25,"email":183},"Laura Parisi, LPN","631-675-5146","lparisi@nycancer.com",{"name":185,"role":33,"phone":186,"phoneExt":25,"email":187},"Lauren Gianelli-Bilka, LPN","631-675-5256","lgianelli@nycancer.com",{"name":189,"role":61,"phone":25,"phoneExt":25,"email":25},"Richard Zuniga, MD",{"type":191,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100462691","phase-1-fih-study-of-rgt-419b-alone-and-with-endocrine-therapy-in-hr-positive-her2-negative-advancedmetastatic-breast-cancer-100462691",false,"NCT05304962","FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced\u002FMetastatic Breast Cancer","First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced\u002FMetastatic Breast Cancer","Inclusion Criteria:\n\n1. Male or female \\>\u002F= 18 years old\n2. ECOG Performance Status 0 to 1\n3. Subjects must have histologically or cytologically confirmed diagnosis of ER+, HER2- ABC consistent with ASCO CAP guidelines that is locally advanced and unresectable (Stage III) or metastatic (Stage IV) BC.\n4. Measurable AND evaluable lesions at baseline per RECIST v1.1.\n5. Eligible subjects must meet all of the following criteria:\n\n   * Progression after receiving 1 line of prior cyclin-dependent kinase 4 and 6 inhibitor (CDK4\u002F6i) therapy combined with HT in the MBC setting (up to 1 additional line of CDK4\u002F6i is permitted in the post-surgical adjuvant setting);\n\n     * Subjects must have received therapy for ≥3 months in the MBC setting, or for ≥6 months in the adjuvant setting, prior to progression\n   * Progression after ≤3 lines of prior HT therapy (regardless of whether it is HT alone or in combination with other therapies)\n\n     * Prior HT combination agents, including SERD, SERM or AI, must have received formal approval by regulatory agency.\n   * ≤ 1 prior line of chemotherapy in the metastatic setting\n6. Adequate organ function\n7. Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Presence of visceral metastases with severe organ dysfunction as evidence by signs and symptoms, laboratory studies, lymphangitic spread and\u002For rapid progression of disease\n2. Pregnant or planning to become pregnant\n3. Prior irradiation to \\>25% of the bone marrow and\u002For inadequate bone marrow function or evidence of clinically significant end-organ damage\n4. Major surgery, chemotherapy, targeted therapy, experimental agents, or radiation within 14-28 days prior to Cycle 1, Day 1\n5. Active, serious medical condition that is not well controlled with locally approved medications allowed by the protocol\n6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in the study","ALL","18 Years",{"count":202,"type":203},64,"ESTIMATED","INTERVENTIONAL",[206],"PHASE1","This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4\u002F6i plus hormonal therapy.",[209],"Breast Cancer",[209],"2026-03-27",{"date":213,"type":214},"2026-04-02","ACTUAL",{"date":216,"type":214},"2022-03-04",{"date":218,"type":203},"2026-12-30",{"name":5,"class":6},8]